A detailed history of California Public Employees Retirement System transactions in Exelixis, Inc. stock. As of the latest transaction made, California Public Employees Retirement System holds 1,392,425 shares of EXEL stock, worth $47.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,392,425
Previous 1,464,672 4.93%
Holding current value
$47.9 Million
Previous $32.9 Million 9.79%
% of portfolio
0.03%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$21.96 - $27.6 $1.59 Million - $1.99 Million
-72,247 Reduced 4.93%
1,392,425 $36.1 Million
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $9.58 Million - $11.2 Million
-471,150 Reduced 24.34%
1,464,672 $32.9 Million
Q1 2024

Apr 30, 2024

SELL
$20.17 - $23.93 $775,919 - $920,563
-38,469 Reduced 1.95%
1,935,822 $45.9 Million
Q4 2023

Feb 01, 2024

BUY
$19.25 - $24.13 $3.91 Million - $4.9 Million
203,163 Added 11.47%
1,974,291 $47.4 Million
Q3 2023

Nov 02, 2023

BUY
$19.04 - $22.74 $10 Million - $12 Million
526,814 Added 42.34%
1,771,128 $38.7 Million
Q2 2023

Aug 09, 2023

BUY
$18.17 - $20.48 $3.25 Million - $3.66 Million
178,688 Added 16.77%
1,244,314 $23.8 Million
Q1 2023

May 12, 2023

SELL
$16.3 - $19.41 $175,599 - $209,103
-10,773 Reduced 1.0%
1,065,626 $20.7 Million
Q4 2022

Feb 08, 2023

BUY
$14.96 - $17.39 $4.99 Million - $5.8 Million
333,555 Added 44.9%
1,076,399 $17.3 Million
Q3 2022

Nov 09, 2022

BUY
$15.68 - $22.27 $2.31 Million - $3.29 Million
147,558 Added 24.79%
742,844 $11.6 Million
Q2 2022

Aug 10, 2022

SELL
$17.44 - $23.16 $223,092 - $296,262
-12,792 Reduced 2.1%
595,286 $12.4 Million
Q1 2022

May 04, 2022

SELL
$17.03 - $22.67 $830,927 - $1.11 Million
-48,792 Reduced 7.43%
608,078 $13.8 Million
Q4 2021

Feb 10, 2022

SELL
$15.84 - $21.88 $597,912 - $825,904
-37,747 Reduced 5.43%
656,870 $12 Million
Q3 2021

Nov 10, 2021

SELL
$16.3 - $21.14 $13,088 - $16,975
-803 Reduced 0.12%
694,617 $14.7 Million
Q2 2021

Aug 13, 2021

SELL
$17.95 - $25.56 $535,861 - $763,042
-29,853 Reduced 4.12%
695,420 $12.7 Million
Q1 2021

May 14, 2021

SELL
$20.53 - $25.22 $593,645 - $729,261
-28,916 Reduced 3.83%
725,273 $16.4 Million
Q4 2020

Feb 02, 2021

BUY
$18.39 - $24.8 $1.01 Million - $1.36 Million
54,657 Added 7.81%
754,189 $15.1 Million
Q3 2020

Nov 05, 2020

BUY
$20.67 - $26.94 $379,335 - $494,402
18,352 Added 2.69%
699,532 $17.1 Million
Q2 2020

Aug 12, 2020

BUY
$16.46 - $27.42 $168,978 - $281,493
10,266 Added 1.53%
681,180 $16.2 Million
Q1 2020

May 12, 2020

SELL
$14.46 - $21.8 $638,495 - $962,600
-44,156 Reduced 6.18%
670,914 $11.6 Million
Q4 2019

Jan 27, 2020

BUY
$15.15 - $18.89 $608,742 - $759,019
40,181 Added 5.95%
715,070 $12.6 Million
Q3 2019

Oct 31, 2019

BUY
$17.68 - $22.65 $3.74 Million - $4.79 Million
211,697 Added 45.7%
674,889 $11.9 Million
Q2 2019

Aug 15, 2019

BUY
$18.93 - $24.75 $661,149 - $864,418
34,926 Added 8.16%
463,192 $9.9 Million
Q1 2019

May 03, 2019

BUY
$19.6 - $24.76 $275,928 - $348,571
14,078 Added 3.4%
428,266 $10.2 Million
Q4 2018

Feb 08, 2019

SELL
$13.65 - $21.8 $465,628 - $743,641
-34,112 Reduced 7.61%
414,188 $8.15 Million
Q3 2018

Nov 13, 2018

SELL
$15.87 - $22.4 $782,232 - $1.1 Million
-49,290 Reduced 9.91%
448,300 $7.94 Million
Q2 2018

Aug 15, 2018

SELL
$18.56 - $22.45 $2.84 Million - $3.44 Million
-153,113 Reduced 23.53%
497,590 $10.7 Million
Q1 2018

May 11, 2018

SELL
$22.15 - $31.89 $974,644 - $1.4 Million
-44,002 Reduced 6.33%
650,703 $14.4 Million
Q4 2017

Feb 06, 2018

BUY
$24.23 - $30.93 $755,152 - $963,964
31,166 Added 4.7%
694,705 $21.1 Million
Q3 2017

Nov 15, 2017

BUY
$23.35 - $29.24 $15.5 Million - $19.4 Million
663,539
663,539 $16.1 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.1B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.